molecules-logo

Journal Browser

Journal Browser

Nanomaterials for Cancer Diagnosis and Therapy II

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Nanochemistry".

Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 2596

Special Issue Editors


E-Mail Website
Guest Editor
School of Mechanical Engineering and IT, Yeungnam University, Gyeongsan 38541, Korea
Interests: nanotechnology; 2D nanoparticles; theranostics; cancer therapy; biocompatibility; detection

E-Mail Website
Guest Editor
Department of Biotechnology, Indian Institute of Technology, Roorkee 247667, India
Interests: theranostics; cancer therapy; biocompatibility; drug delivery; toxicology; screening; targeting moieties

E-Mail Website
Guest Editor
School of Mechanical Engineering and IT, Yeungnam University, Gyeongsan 38541, Korea
Interests: nanotechnology; 2D nanoparticles; cancer therapy; biocompatibility; drug delivery; toxicology

Special Issue Information

Dear Colleagues,

Nanotechnology has become a powerful weapon in the fight against cancer. With the development of precisely engineered nanoparticles able to overcome biological barriers, they specifically recognize and destroy a single type of cancer cell, and accumulate preferentially in tumors, offering a new and potent arsenal to oncologists. Inorganic and organic (or polymeric) nanoparticles have been widely explored for therapeutic and diagnostic applications in cancer treatment. Normally, single nanoparticles are often used and functionalized with organic or polymeric ligands to improve their stability, biocompatibility, and functionality. While individual nanoparticles are no doubt exciting, an ensemble of interacting nanoparticles can exhibit a rich variety of novel and extremely useful collective properties that can be radically different from their individual characteristics. These new synergistic properties originate from coupling interactions in the ensemble of nanoparticles. It is, therefore, expected that the ability to design hybrid structures with tailored spatial arrangements of nanoparticles may facilitate the utilization of nanoparticles in biomedical applications. Recent advances in nanomedicine have raised exciting possibilities for future nanoparticle applications in personalized cancer therapy, and new strategies for building hybrid nanostructures are offering interesting platforms, such as effective multimodality cancer imaging (i.e., photothermal, photoacoustic, and magnetic resonance imaging) and combinational cancer therapy (i.e., the photothermal ablation of tumors, photodynamic therapy, and targeted delivery-based chemotherapy).

In this Special Issue, we invite investigators to contribute original research and review articles related to the application of hybrid nanoparticles as multifunctional platforms in the treatment and early diagnosis of cancer, with particular interest in research directed toward improving the effectivity and selectivity properties of different nanoparticles for treatment or bioimaging purposes. Potential topics include, but are not limited to:

  • Theranostic nanoparticles for cancer treatment;
  • Nanoparticles as contrast agents for bioimaging;
  • Nanoparticles as biosensors;
  • Novel therapies based on nanomaterials for cancer treatment and diagnosis;
  • Clinical studies and therapeutic and diagnostic efficacy of anticancer nanoparticles;
  • Biocompatibility and toxicity studies of nanoparticles for cancer treatment.

Prof. Dr. Tapas K. Mandal
Prof. Dr. Partha Roy
Dr. Nargish Parvin
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanotechnology
  • hybrid nanoparticles
  • theranostics
  • cancer therapy
  • biocompatibility
  • imaging
  • drug delivery

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 2528 KiB  
Article
CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells
by Noah Trac, Hyun Seok Oh, Leila Izzy Jones, Randy Caliliw, Shinji Ohtake, Brian Shuch and Eun Ji Chung
Molecules 2022, 27(23), 8457; https://doi.org/10.3390/molecules27238457 - 2 Dec 2022
Cited by 5 | Viewed by 2341
Abstract
The majority of clear cell renal cell carcinomas (ccRCCs) are characterized by mutations in the Von Hippel–Lindau (VHL) tumor suppressor gene, which leads to the stabilization and accumulation of the HIF2α transcription factor that upregulates key oncogenic pathways that promote glucose [...] Read more.
The majority of clear cell renal cell carcinomas (ccRCCs) are characterized by mutations in the Von Hippel–Lindau (VHL) tumor suppressor gene, which leads to the stabilization and accumulation of the HIF2α transcription factor that upregulates key oncogenic pathways that promote glucose metabolism, cell cycle progression, angiogenesis, and cell migration. Although FDA-approved HIF2α inhibitors for treating VHL disease-related ccRCC are available, these therapies are associated with significant toxicities such as anemia and hypoxia. To improve ccRCC-specific drug delivery, peptide amphiphile micelles (PAMs) were synthesized incorporating peptides targeted to the CD70 marker expressed by ccRCs and anti-HIF2α siRNA, and the ability of HIF2α-CD27 PAMs to modulate HIF2α and its downstream targets was evaluated in human ccRCC patient-derived cells. Cell cultures were derived from eight human ccRCC tumors and the baseline mRNA expression of HIF2A and CD70, as well as the HIF2α target genes SLC2A1, CCND1, VEGFA, CXCR4, and CXCL12 were first determined. As expected, each gene was overexpressed by at least 63% of all samples compared to normal kidney proximal tubule cells. Upon incubation with HIF2α-CD27 PAMs, a 50% increase in ccRCC-binding was observed upon incorporation of a CD70-targeting peptide into the PAMs, and gel shift assays demonstrated the rapid release of siRNA (>80% in 1 h) under intracellular glutathione concentrations, which contributed to ~70% gene knockdown of HIF2α and its downstream genes. Further studies demonstrated that knockdown of the HIF2α target genes SLC2A1, CCND1, VEGFA, CXCR4, and CXCL12 led to inhibition of their oncogenic functions of glucose transport, cell proliferation, angiogenic factor release, and cell migration by 50–80%. Herein, the development of a nanotherapeutic strategy for ccRCC-specific siRNA delivery and its potential to interfere with key oncogenic pathways is presented. Full article
(This article belongs to the Special Issue Nanomaterials for Cancer Diagnosis and Therapy II)
Show Figures

Figure 1

Back to TopTop